Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer

BACKGROUND: Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment with necroptosis-inducing small molecules to overcome chemotherapeutic resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyung-Min, Lee, Hyebin, Han, Dohyun, Moon, Woo Kyung, Kim, Kwangsoo, Oh, Hyeon Jeong, Choi, Jinwoo, Hwang, Eun Hye, Kang, Seong Eun, Im, Seock-Ah, Lee, Kyung-Hun, Ryu, Han Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687715/
https://www.ncbi.nlm.nih.gov/pubmed/33239070
http://dx.doi.org/10.1186/s13058-020-01367-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687715/
https://www.ncbi.nlm.nih.gov/pubmed/33239070
http://dx.doi.org/10.1186/s13058-020-01367-7

Ejemplares similares